Company: LGNZZ
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0000886163-25-000036
Chunk: 58

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-05-09
Form: 10-Q
Item: Item 8
Chunk 58
---
21,587 18,357 Qarziba5,442 — Other460 738 Income from financial royalty assets5,902 738 Total royalties27,489 19,095 Captisol13,460 9,212 Contract revenue and other incomeMilestone and other4,384 727 Other income— 1,944 Contract revenue and other income4,384 2,671 Total$45,333 $30,978 

12

Short-term InvestmentsOur short-term investments consist of the following at March 31, 2025 and December 31, 2024 (in thousands):March 31, 2025Amortized costGross unrealized gainsGross unrealized lossesEstimated fair value     U.S. Treasuries$64,970 $5 $(7)$64,968      Commercial paper29,311 5 (7)29,309      Corporate notes/bonds18,278 17 (10)18,285      Certificates of Deposit17,093 6 (1)17,098      Corporate equity securities5,529 3,402 (1,829)7,102 $135,181 $3,435 $(1,854)136,762       Viking common stock24,150 Total short-term investments$160,912 December 31, 2024     U.S. Treasuries$78,442 $19 $(13)$78,448      Commercial paper23,483 5 (6)23,482      Certificates of Deposit22,812 12 (4)22,820      Corporate notes/bonds15,496 21 (8)15,509      Corporate equity securities9,954 — (6,595)3,359 $150,187 $57 $(6,626)143,618      Viking common stock40,240 Total short-term investments$183,858 During the three months ended March 31, 2024, we sold 0.7 million shares of Viking common stock and recognized a realized gain of $60.0 million in total. During the three months ended March 31, 2025, we did not sell any shares of Viking common stock. Gain (loss) from short-term investments in our condensed consolidated statements